Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Gefitinib Tablets in Healthy Chinese Male Subjects
NCT03050164Phase 1Completed
- Sponsor
- Hunan Kelun Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hunan Kelun Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 216 hours and Area Under the Curve at 216 hours. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03050164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050164.